Biodegradable Polymer DES (Ultimaster) vs. Magnesium Bioresorbable Scaffold (BRS Magmaris) in Diabetic Population with NSTE-ACS: A One-Year Clinical Outcome of Two Sirolimus-Eluting Stents

Table 1

Baseline clinical characteristics of both study arms.

	Magmaris group			Ultimaster group
	Diabetes; ()	Nondiabetes; ()	value	Diabetes; ()	Non diabetes; ()	value
Age (years)
NSTEMI	58 (80.5%)	92 (76.0%)		32 (54.2%)	56 (50.1%)
Unstable angina	14 (19.5%)	16 (13.2%)		27 (45.8%)	54(49.9%)
Oral anti-diabetic treatment	58 (80.5%)	NA	—	45 (76.3%)	NA	—
Insulin	14 (19.5%)	NA	—	14 (23.7%)	NA	—
Hypertension	69 (95.8%)	102 (84.2%)		58 (98.3%)	100 (90.1%)
Hyperlipidemia	58 (80.5%)	94 (77.0%)		47 (79.6%)	83 (75.5%)
Atrial fibrillation	2 (2.7%)	7 (5.7%)		11 (18.6%)	13 (11.8%)
Post PCI status	36 (50%)	42 (34.7%)		27 (46.5%)	34 (30.9%)
Primary diagnosis of MI	28 (38.8%)	31 (25.6%)		26 (44.1%)	34 (30.9%)
LVEF
Total cholesterol (mmol/L)
LDL (mmol/L)
Triglycerides (mmol/L)
Creatine (μmol/L)

Abbreviations: NSTEMI: no ST-elevation myocardial infarction; PCI: percutaneous coronary intervention; MI: myocardial Infarction; LVEF: left ventricle ejection fraction.